Erectile Dysfunction

An Update on Pharmacological Treatment of Erectile Dysfunction Erectile dysfunction (ED) is a highly prevalent disease that is expected to affect 322 million men by 2025.

Treatment of Erectile Dysfunction Erectile dysfunction (ED) has clearly emerged as one of the significant medical problems of the 21st century.

Managing Erectile Dysfunction from the Point of View of the Couple Male diabetic patients who attend a diabetic routine year program visit will be asked to give their voluntary permission to fill out a questionnaire on possible erectile dysfunction.

• Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factors
• Incidence of erectile dysfunction in Italian men with diabetes
• Ten-year incidence of self-reported erectile dysfunction in people with long-term type 1 diabetes
• Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction
• Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study

• Erectile potentials of a new phosphodiesterase type 5 inhibitor, DA-8159, in diet-induced obese rats
• The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats
• Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes
• Penile erectile responses to electric stimulation are enhanced by a new phosphodiesterase type-5 inhibitor
• Effect of a Chinese herbal medicine mixture on a rat model of hypercholesterolemic erectile dysfunction

• To evaluate the impact of nightly sildenafil vs placebo use on diabetic men with and without proven endothelial dysfunction and coexisting erectile concerns.
• To determine if chronic sildenafil use compared to placebo positively impacts endothelial function among a cohort of diabetic mend with erectile dysfunction
• To assess the salvage rate of sildenafil - failures who demonstrate improved response rates over time with chronic use
• To assess if microalbuminuria predicts flow-mediated dilation (FMD) response
• To measure and identify if other patient specific characterisics predict for sildenafil erectile response and flow-mediated dilataiton (FMD) response over time (patient specifics; blood pressure, HBA1c, weight, BMI, age IIEF score at baseline)

• Cardiovascular risk factors determine erectile and arterial function response to sildenafil
• Endothelial microparticles correlate with erectile dysfunction in diabetic men
• Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database
• Efficacy of sildenafil in erectile dysfunction after radical prostatectomy
• Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results

• The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction
• PDE5 inhibitors: are there differences?
• Phosphodiesterase 5 inhibitors for erectile dysfunction
• Clinical monograph for drug formulary review: erectile dysfunction agents
• Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction